2020年3月4日 · Gene therapy with adeno-associated virus (AAV) vectors has demonstrated safety and long-term efficacy in a number of trials across target organs, including eye, liver, …

2022年8月12日 · Gene transfer using adeno-associated viral (AAV) vectors has made tremendous progress in the last decade and has achieved cures of debilitating diseases such …

AAV infections are asymptomatic, and the virus persist for the lifetime of an individual. Nevertheless, AAVs are immunogenic as they stimulate detectable B and T cell responses . …

2024年1月20日 · This review focuses on aspects of immunity against rAAV, mediated by anti-AAV neutralizing antibodies (NAbs) arising after natural exposure to AAVs or after rAAV vector …

Gene therapy with adeno-associated virus (AAV) vectors has demonstrated safety and long-term efficacy in a number of trials across target organs, including eye, liver, skeletal muscle, and …

2022年9月22日 · Immunogenicity has imposed a challenge to efficacy and safety evaluation of adeno-associated virus (AAV) vector-based gene therapies. Mild to severe adverse events …

2023年3月2日 · Multiple factors, including vector design, dose, and route of administration, contribute to the overall immunogenicity of AAVs. The immune responses against the AAV …

2018年10月10日 · Gene transfer with adeno-associated virus (AAV) vectors has yielded clinically relevant results in several preclinical and clinical studies, with several candidate treatments …

2020年3月4日 · Gene therapy with adeno-associated virus (AAV) vectors has demonstrated safety and long-term efficacy in a number of trials across target organs, including eye, liver, …

2018年10月3日 · Gene transfer with adeno-associated virus (AAV) vectors has yielded clinically relevant results in several preclinical and clinical studies, with several candidate treatments …